Canopy Growth (CGC) Earnings Date & Reports

Key Takeaways

• Consolidated net revenue rose 22% year over year to C$81.4 million, but came in modestly below analyst consensus estimates.
• International markets cannabis net revenue surged 141% to C$12.3 million, driven by strong European sales in Germany and Poland.
• Canada Medical revenue climbed 18% to C$25.8 million, while Canada Adult Use revenue increased 17% to C$28.1 million.
• Storz & Bickel revenue slipped 4% to C$15.1 million on softer consumer spending.
• Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) loss narrowed to C$2.9 million.
• Net loss widened year over year, weighed down by C$35.8 million in fair-value charges tied to Canopy USA assets.
• For more on Canopy Growth, explore its Major News, Today's Price Move, Price Targets, and Forecast pages.
• Discover actionable market ideas with Trending AI Robots.

Earnings Context and Why It Matters

Canopy Growth reported its second quarter fiscal 2027 results, covering the three months ended September 30, 2026, on November 6, 2026. The report matters because it offers the clearest test yet of whether the company can convert its international expansion and cost discipline into a sustainable path toward profitability. Over the prior fiscal year, Canopy reset its business, completed the acquisition of MTL Cannabis, and moved to a net cash position. Investors are closely watching whether rising overseas cannabis sales and the integration of MTL can offset headwinds from the Veterans Affairs Canada reimbursement reduction and softening demand in the company's vaporizer segment.

Reported Results

Canopy Growth posted consolidated net revenue of C$81.4 million for Q2 FY2027, a 22% increase year over year, but slightly below analyst expectations. Cannabis net revenue grew 30% to C$66.2 million, with the international markets cannabis segment the standout, rising 141% to C$12.3 million on strong demand in Germany and Poland.

Within Canada, medical cannabis revenue increased 18% to C$25.8 million, while adult-use cannabis revenue rose 17% to C$28.1 million. The Storz & Bickel vaporizer segment declined 4% to C$15.1 million amid softer consumer spending. Adjusted gross margin came in at 31%, down from 33% a year earlier, partly reflecting the Veterans Affairs Canada reimbursement-rate reduction.

The adjusted EBITDA loss improved to C$2.9 million, narrowing sequentially from the prior quarter. However, net loss widened by roughly C$35.7 million year over year, largely due to C$35.8 million in fair-value charges related to Canopy USA assets. The company ended the quarter with C$320 million in cash and short-term investments, and management reaffirmed its expectation of reaching positive adjusted EBITDA during fiscal 2027.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore the AI Screener to uncover setups that match your own criteria.

Market Reaction and Investor Sentiment

Shares of Canopy Growth traded lower on Friday following the report, as investors weighed the revenue miss and the wider net loss against the company's accelerating international momentum. The top-line shortfall against consensus, combined with the C$35.8 million fair-value charges tied to Canopy USA assets, appeared to temper enthusiasm even as the underlying cannabis business delivered solid double-digit growth. Investor sentiment around Canopy remains centered on the credibility of its profitability timeline, with the narrowing adjusted EBITDA loss providing a modest positive signal that cost controls and integration synergies are beginning to flow through the income statement.

Forward Outlook and Key Factors to Monitor

Looking ahead, Canopy Growth has signaled that year-over-year improvements should be more pronounced in the second half of fiscal 2027, supported by seasonality in the Storz & Bickel business and the continued flow-through of cost savings. Management has reiterated its line of sight to positive adjusted EBITDA during the fiscal year, a milestone investors will be tracking closely in the coming quarters.

Several factors will shape the path forward. First, cultivation improvements at the Kincardine facility are expected to drive higher yield and flower quality, with a noticeable impact beginning as the company exits the third quarter. Second, recently obtained EU GMP (European Union Good Manufacturing Practice) certifications at both Smiths Falls and Kincardine could broaden Canopy's product offering in Europe beyond flower, expanding its addressable market.

Investors should also monitor the ongoing impact of the Veterans Affairs Canada reimbursement reduction on the Canadian medical segment, as well as demand trends in the Storz & Bickel segment, which has faced softer consumer spending. Finally, Canopy's strong cash position gives it flexibility for selective M&A (mergers and acquisitions) or other strategic opportunities, while a potential share consolidation remains available if needed to maintain its Nasdaq listing.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations